Revolution Medicines Built a $4.3 Billion Wall Around Daraxonrasib
Revolution Medicines Daraxonrasib: The $4.3B Autopsy | Witfire Elite View Witfire Elite Oncology Strategy Case Studies Financing Long Read Pharma Market Case Studies Witfire Elite View Revolution Medicines Built a $4.3 Billion Wall Around Daraxonrasib Phase 3 Data, Capital Structure and the Cost of Independence Revolution Medicines has not eliminated acquisition interest. It has eliminated the financial urgency that could…
Trending News
Philippines AI Liver Cancer Breakthrough: How the CANDLE Study Could Change Early Detection
Philippines AI Liver Cancer Breakthrough: How the CANDLE Study Could Change Early Detection…
Pharma Stock Market News: US-Israel-Iran War Impact on Drug Supply Chains, Oil Prices and Healthcare Stocks
The stock market is now looking at the US-Israel-Iran conflict through a sharper…
Pharma Stock Market News: US-Israel-Iran War Impact on Drug Companies, Oil Prices, and Pharma Supply Chains
The US-Israel-Iran war is affecting pharma stocks, drug supply chains, logistics costs, cold-chain…
Moderna Flu Vaccine Reversal: FDA Refused to Review It—Then Advisers Voted 9-0 Twice
Moderna Flu Vaccine: From FDA Refusal to Two 9-0 Votes | Witfire Elite…
Editorial picks
Revolution Medicines Built a $4.3 Billion Wall Around Daraxonrasib
Revolution Medicines Daraxonrasib: The $4.3B Autopsy | Witfire Elite View Witfire Elite Oncology Strategy Case Studies Financing Long Read Pharma Market Case Studies Witfire Elite View Revolution Medicines Built a $4.3 Billion Wall Around Daraxonrasib Phase 3 Data, Capital Structure and the Cost of Independence Revolution Medicines has not eliminated…
Pharma Stock Market News: US-Israel-Iran War Impact on Drug Companies, Oil Prices, and Pharma Supply Chains
Moderna Flu Vaccine Reversal: FDA Refused to Review It—Then Advisers Voted 9-0 Twice
Lilly’s Germany Investment Cut: Why Pharma Capital Is Starting to Vote Against Policy Risk
Iran War Pharma Shock: Why India’s API Dependence Hurts More Than China’s Biotech Lead
Categories
Investments
business news
Entrepreneurship
Startups
June, 2026
Chokepoints & Catalysts — Vol. I, No. 1
Five intelligence-led analyses on how FDA decisions, geopolitical chokepoints, and policy shifts are repricing global pharma—covering GSK’s Nuvalent acquisition, Replimune’s RP1, India’s CRO opportunity, API dependence, and Lilly’s Germany investment cut.
Around The World
GSK Bought September and November 2026: The $10.6 Billion Nuvalent Autopsy
GSK Did Not Simply Buy Nuvalent. It Bought Two FDA Decision Dates | Witfire Elite View Witfire Elite Oncology M&A Case Studies Strategy Long Read Pharma Market Case Studies Witfire Elite View GSK Did Not Simply Buy Nuvalent It Bought Two FDA Decision Dates, a Shortcut into Lung Cancer, and Pre-Approval Regulatory Proximity GSK’s $10.6 billion agreement to acquire Nuvalent…
Pharma News
Revolution Medicines Built a $4.3 Billion Wall Around Daraxonrasib
Revolution Medicines Daraxonrasib: The $4.3B Autopsy | Witfire Elite View Witfire Elite Oncology Strategy Case Studies Financing Long…
Moderna Flu Vaccine Reversal: FDA Refused to Review It—Then Advisers Voted 9-0 Twice
Moderna Flu Vaccine: From FDA Refusal to Two 9-0 Votes | Witfire Elite View Witfire Elite FDA &…
GSK Bought September and November 2026: The $10.6 Billion Nuvalent Autopsy
GSK Did Not Simply Buy Nuvalent. It Bought Two FDA Decision Dates | Witfire Elite View Witfire Elite…